|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-2-4
|
|
pubmed:abstractText |
Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl-modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA, has a prolonged tissue half life, enhances drug efficacy in xenograft models, and reduces clusterin expression in humans with a biologically effective dose of 640 mg. The objective of this study was to determine a recommended phase II dose of OGX-011 in combination with docetaxel.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:ChiKim NKN,
pubmed-author:EisenhauerElizabethE,
pubmed-author:GleaveMartinM,
pubmed-author:GunsEmmaE,
pubmed-author:HirteHalH,
pubmed-author:HotteSebastien JSJ,
pubmed-author:KnoxJenniferJ,
pubmed-author:KollmansbergerChristianC,
pubmed-author:PowersJeanJ,
pubmed-author:SiuLillian LLL,
pubmed-author:TuDongshengD,
pubmed-author:WalshWendyW
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
833-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18245546-Antineoplastic Agents,
pubmed-meshheading:18245546-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18245546-Clinical Trials, Phase II as Topic,
pubmed-meshheading:18245546-Clusterin,
pubmed-meshheading:18245546-Humans,
pubmed-meshheading:18245546-Neoplasms,
pubmed-meshheading:18245546-Oligonucleotides, Antisense,
pubmed-meshheading:18245546-Taxoids,
pubmed-meshheading:18245546-Thionucleotides
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
|
|
pubmed:affiliation |
British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada. kchi@bccancer.bc.ca
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
